MX2022014410A - Il1-r1 derived inhibitor of il-1b and use thereof. - Google Patents

Il1-r1 derived inhibitor of il-1b and use thereof.

Info

Publication number
MX2022014410A
MX2022014410A MX2022014410A MX2022014410A MX2022014410A MX 2022014410 A MX2022014410 A MX 2022014410A MX 2022014410 A MX2022014410 A MX 2022014410A MX 2022014410 A MX2022014410 A MX 2022014410A MX 2022014410 A MX2022014410 A MX 2022014410A
Authority
MX
Mexico
Prior art keywords
human
heterodimeric protein
protein assembly
1racp
mutants
Prior art date
Application number
MX2022014410A
Other languages
Spanish (es)
Inventor
Yan Lavrovsky
Alexey Repik
Mikhail Samsonov
Vasily Ignatiev
Sergei Barbashov
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of MX2022014410A publication Critical patent/MX2022014410A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

A therapeutic composition is described that can be used for treating or prevention of diseases association with modulation of activity of human IL-1β. In certain aspects, the disclosed composition is based on engineering of a heterodimeric protein assembly that is capable of binding to human IL-1β and attenuating its function. The heterodimeric protein assembly comprises extracellular portions of human IL1-R1 and of human IL-1RAcP, or their functional fragments. Each, the IL1-R1 portion and the IL-1RAcP portion, is fused to a distinct mutant of Fc portion of the human Ig Gamma-1. The two distinct Fc mutants in the heterodimeric protein assembly are engineered as to favor the heteromeric dimer formation between the two Fc mutants over any homomeric assembly. The therapeutic composition has been formulated for administration into humans and animals.
MX2022014410A 2020-05-22 2020-05-22 Il1-r1 derived inhibitor of il-1b and use thereof. MX2022014410A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2020/034114 WO2021236091A1 (en) 2020-05-22 2020-05-22 Il1-r1 derived inhibitor of il-1b and use thereof

Publications (1)

Publication Number Publication Date
MX2022014410A true MX2022014410A (en) 2022-12-06

Family

ID=78708753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014410A MX2022014410A (en) 2020-05-22 2020-05-22 Il1-r1 derived inhibitor of il-1b and use thereof.

Country Status (6)

Country Link
EP (1) EP4153613A4 (en)
JP (1) JP2023527171A (en)
CN (1) CN115768787A (en)
BR (1) BR112022022089A2 (en)
MX (1) MX2022014410A (en)
WO (1) WO2021236091A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3905921B2 (en) * 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー COMPOSITION CONTAINING COAGULATION FACTOR VIII, METHOD FOR PRODUCING THE SAME, AND METHOD FOR USING SURFACTANT AS STABILIATOR
JP6225197B2 (en) * 2013-02-15 2017-11-01 アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ IL-1β inhibitor composition and use thereof
US11155600B2 (en) * 2014-03-24 2021-10-26 R-Pharm Overseas, Inc. Human IL1-R1 derived inhibitor of IL-1β

Also Published As

Publication number Publication date
CN115768787A (en) 2023-03-07
WO2021236091A1 (en) 2021-11-25
BR112022022089A2 (en) 2022-12-13
EP4153613A1 (en) 2023-03-29
EP4153613A4 (en) 2024-01-24
JP2023527171A (en) 2023-06-27

Similar Documents

Publication Publication Date Title
PH12015501796A1 (en) Il-1b inhibitor composition and use thereof
CA2123049C (en) Pharmaceutical containing the p40 subunit of interleukin 12
DE69839278D1 (en) SUBSTITUTED PYRIDINE AND PYRIDAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
IL125711A0 (en) Human metabotropic glutamate receptor
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
HK1029123A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
RU2008136324A (en) GASTROINTESTINAL PROLIFERATIVE FACTOR AND ITS APPLICATIONS
DE60039240D1 (en) NEOVASCULAR IMMUNOJUGATE
JPH02109994A (en) Monoclonal antibody and in-vitro and in-vivo neutralization of toxity of tnf-alpha by fregment induced from said antibody
EP1543158A4 (en) Regulated aptamer therapeutics
MX2022014410A (en) Il1-r1 derived inhibitor of il-1b and use thereof.
KR980002066A (en) Mutant human growth hormone and uses thereof
ATE341316T1 (en) CONTROL WOUND CARRING WITH CALMODULIN INHIBITORS OR PROTEIN KINASE C INHIBITORS
Peel et al. Localized neuropathy following jellyfish sting
AU6232298A (en) Ointment for the treatment of burns and of other skin diseases
WO2004007557A3 (en) Tf antagonist
KR960701649A (en) Novel Polypeptides with Factor Xa Inhibitory Activity
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
Watt The toxic effects of the bite of a clubionid spider
Tang et al. Expression and characterization of recombinant canine IL-13 receptor α2 protein and its biological activity in vitro
Matthews et al. Multiple seagull flaps for digital contractures in electrical burns
NO20000007D0 (en) Use of growth hormone in compositions to treat insulin resistance in the heart and to increase protein kinase B (PKB) activity
Butler et al. Thermal injuries to free flaps: better prevented than treated
CN1762390B (en) Burn and boil medicine and its preparation method
Holton ART. VIII.--Remarkable Instance of Burns from Lighting.